Nektar, AZN in opioid constipation deal

Nektar Therapeutics (NASDAQ:NKTR) granted AstraZeneca plc (LSE:AZN; NYSE:AZN) exclusive, worldwide rights to NKTR-118 and NKTR-119. Nektar will receive $125 million up front and could receive $610 million in milestones for NKTR-118 and $385 million in milestones on each of the first two compounds from the NKTR-119 program, as well as tiered, double-digit royalties on both programs. ...